Nasus Pharma Ltd. (NSRX) Key Metrics
NSRX valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $37.2M
- Enterprise value
- $30.1M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 3.8
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- —
NSRX key metrics, 2022–2025
Fiscal year ended December 31, 2025 · U.S. dollarsNSRX returns How much profit the business earns on the capital it uses.
NSRX per-share figures Results divided by the shares outstanding at year-end.
NSRX financial health Debt, liquidity and how easily interest is covered.
NSRX valuation history
NSRX returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
NSRX debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
NSRX price vs earnings per share
NSRX key metrics
2022–2025| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Valuation | ||||
| Market capitalization | $73.3M | — | — | — |
| Enterprise value | $69.1M | — | — | — |
| Price / book | 26.5 | — | — | — |
| Earnings yield | −8.0% | — | — | — |
| Free cash flow yield | −6.7% | — | — | — |
| Share price at fiscal year-end | $9.15 | — | — | — |
| Per share | ||||
| Revenue per share | $0.00 | $0.00 | $0.00 | $0.00 |
| Earnings per share | −$0.73 | −$0.17 | −$0.12 | −$0.19 |
| Operating cash flow per share | −$0.61 | −$0.07 | −$0.11 | −$0.13 |
| Free cash flow per share | −$0.62 | −$0.07 | −$0.11 | −$0.13 |
| Cash per share | $0.54 | $0.03 | $0.02 | $0.02 |
| Book value per share | $0.35 | −$0.35 | −$0.42 | −$0.31 |
| Tangible book value per share | $0.35 | −$0.35 | −$0.42 | −$0.31 |
| Capex per share | $0.00 | $0.00 | $0.00 | $0.00 |
| Debt per share | $0.01 | $0.20 | $0.27 | $0.17 |
| Shares outstanding | 8.0M | 9.1M | 9.1M | 9.1M |
| Change in shares outstanding | −11.6% | 0.0% | 0.0% | — |
| Returns & profitability | ||||
| Return on assets (ROA) | −204.7% | −263.9% | −244.1% | −410.3% |
| Return on tangible assets | −117.0% | −213.7% | −236.7% | −410.3% |
| Financial health | ||||
| Total debt | $118,000 | $1.8M | $2.5M | $1.6M |
| Cash & short-term investments | $4.3M | $284,000 | $193,000 | $154,000 |
| Net debt | −$4.2M | $1.5M | $2.3M | $1.4M |
| Debt / equity | 0.04 | — | — | — |
| Debt / assets | 0.02 | 2.51 | 5.53 | 3.77 |
| Current ratio | 2.24 | 0.12 | 0.10 | 0.13 |
| Quick ratio | 2.24 | 0.12 | 0.10 | 0.13 |
| Interest coverage | — | -37.2 | -23.4 | -113.4 |
| Working capital | $2.7M | −$3.5M | −$3.8M | −$2.8M |
| Invested capital | −$1.4M | −$1.7M | −$1.5M | −$1.4M |
| Tangible asset value | $2.8M | −$3.2M | −$3.8M | −$2.8M |
| Net current asset value | $2.6M | −$3.5M | −$3.8M | −$2.8M |
| Graham net-net per share | $0.26 | −$0.40 | −$0.45 | −$0.34 |
| Efficiency | ||||
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Average payables | $740,000 | $653,000 | $713,000 | $771,000 |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from NSRX's annual financial statements (latest annual report filed March 25, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
NSRX valuation and financial ratios
It ended the year with $0.1 million of debt and $4.3 million in cash and short-term investments, a net cash position of $4.2 million.
See the NSRX income statement, the NSRX chart for price history, or the NSRX stock overview for the latest quote and news.
NSRX key metrics FAQ
How much debt does Nasus Pharma have?
Nasus Pharma had total debt of $0.1 million at the end of fiscal 2025, a debt-to-equity ratio of 0.04 and more cash than debt.
What is Nasus Pharma's free cash flow yield?
Nasus Pharma generated -$4.9 million of free cash flow in fiscal 2025, a free cash flow yield of −6.7% on its market value at year-end ($73.3 million).
What is Nasus Pharma's current ratio?
Nasus Pharma's current ratio was 2.24 at the end of fiscal 2025: current assets were 2.24 times current liabilities.